Michael HodgesBack to team
Michael R. Hodges, M.D., BSc.is an infectious disease clinician and RNA medicines drug development executive with 30 years of experience within the biopharmaceutical industry. He is currently Chief Medical Officer (CMO) at Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. In addition, he is a member of the science advisory boards of Arcturus therapeutics, Exicure therapeutics and eFFECTOR therapeutics. Prior to Amplyx he was the CMO for two RNA platform companies, Santaris A/S and Altair Therapeutics Inc., developing drugs for infectious diseases, cancer, metabolic and respiratory diseases. Previously, he served in Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. He was a Non-Executive Director of F2G, an infectious disease biotechnology company from 2010-2014. Dr. Hodges earned his M.D. (MBBS) and BSc. in Pharmacology, from the University of London, UK.